Hospitals Face Profit Squeeze As Policy Risks Grow: Analyst
BofA warns hospitals face profit and volume pressure from policy cuts, favors post-acute care, upgrades Brookdale, and sees select names better positioned to weather challenges.
Robinhood, HCA Healthcare And 2 Other Stocks Insiders Are Selling
The Nasdaq climbed by more than 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Truist Securities Maintains Buy on HCA Healthcare, Raises Price Target to $290
Truist Securities analyst David Macdonald maintains HCA Healthcare (NYSE:HCA) with a Buy and raises the price target from $270 to $290.
Citigroup Maintains Buy on HCA Healthcare, Raises Price Target to $293
Citigroup analyst Jason Cassorla maintains HCA Healthcare (NYSE:HCA) with a Buy and raises the price target from $280 to $293.
Cowen & Co. Maintains Outperform on HCA Healthcare, Raises Price Target to $292
Cowen & Co. analyst Gary Taylor maintains HCA Healthcare (NYSE:HCA) with a Outperform and raises the price target from $238 to $292.
RBC Capital Maintains Outperform on HCA Healthcare, Raises Price Target to $283
RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:HCA) with a Outperform and raises the price target from $239 to $283.
HCA Healthcare Announces Operational Reorganization
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced an organizational change that includes the creation of a third operating group.
The change, which will be
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday’s Mid-Day Session
Gainers
Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 67% to $0.5484 after the company announced divestiture of its inner ear development assets.